ニロチニブ（ENESTop）による持続的なMR4.5達成後の無治療寛解

基本情報

NCT ID

NCT01698905

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

163

治験依頼者名

Novartis

概要

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at least 3 years and have very small amount of leukemia cells remaining after the nilotinib (Tasigna) treatment will qualify for the study.

対象疾患

介入

依頼者（Sponsor）